The serum prolidase enzyme activity as a biomarker for evaluation of the subclinical vascular damage in children with epilepsy

Simple item page
dc.contributor.authorKaracan N.
dc.contributor.authorÇalik M.
dc.contributor.authorKazanasmaz H.
dc.contributor.authorEthemoǧlu O.
dc.contributor.authorGüzelçiçek A.
dc.contributor.authorYaşin S.
dc.contributor.authorKandemir H.
dc.contributor.authorÇeçen E.
dc.date.accessioned2024-07-22T08:07:06Z
dc.date.available2024-07-22T08:07:06Z
dc.date.issued2020
dc.description.abstractBackgroud: Epilepsy is a chronic medical condition requiring long term or even lifelong therapy. Various researches have shown that epilepsy patients have vascular risk factors such as abnormal lipids, insulin, elevated oxidative stress, chronic inflammation, and subclinical atherosclerosis. Objectives: The purpose of the present study was to determine serum prolidase enzyme activity as a biomarker in children taking antiepileptic drug treatment through comparison with control cases. Materials and Methods: The present study group consists of 61 children (20 females, 41 males) with epilepsy and a control group was formed of 32 healthy individuals (14 females, 18 males). Aspectrophotometric method was used to measure serum prolidase enzyme activity. Results: The epilepsy group demonstrated statistically significantly higher prolidase enzyme activity values when compared with the control group (P = 0.003). It was measured that the serum TOS and OSI values were significantly elevated in patients with epilepsy compared to controls (P < 0.001). However, serum TAS values were significantly lower in the epilepsy group than in the control group (P = 0.032). Conclusions: These results supported that epileptic patients taking the antiepileptic treatment had increased serum prolidase enzyme activity, suggesting that it may show an increased risk of subclinical vascular damage related to both chronic inflammation and fibrotic process associated with degenerated collagen turnover. Therefore, serum prolidase enzyme activity could be considered a useful biomarker for evaluation of the subclinical vascular damage in children with epilepsy on some antiepileptic drugs. © 2020 Wolters Kluwer Medknow Publications. All rights reserved.
dc.identifier.DOI-ID10.4103/aian.AIAN_640_19
dc.identifier.issn09722327
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13828
dc.language.isoEnglish
dc.publisherWolters Kluwer Medknow Publications
dc.rightsAll Open Access; Gold Open Access; Green Open Access
dc.subjectbiological marker
dc.subjectcarbamazepine
dc.subjectlamotrigine
dc.subjectlevetiracetam
dc.subjectoxidizing agent
dc.subjectphenobarbital
dc.subjectphenytoin
dc.subjectproline
dc.subjectproline dipeptidase
dc.subjecttopiramate
dc.subjectvalproic acid
dc.subjectantioxidant activity
dc.subjectArticle
dc.subjectatherosclerosis
dc.subjectblood vessel injury
dc.subjectchild
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectcross-sectional study
dc.subjectelectroencephalogram
dc.subjectenzyme activity
dc.subjectepilepsy
dc.subjectfemale
dc.subjecthuman
dc.subjectlipid fingerprinting
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmonotherapy
dc.subjectnuclear magnetic resonance imaging
dc.subjectoxidative stress
dc.subjectprevalence
dc.subjectradiology
dc.subjectrisk factor
dc.subjectspectrophotometry
dc.subjectvasculitis
dc.titleThe serum prolidase enzyme activity as a biomarker for evaluation of the subclinical vascular damage in children with epilepsy
dc.typeArticle

Files

Collections

Scopus Koleksiyonu